Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
645.05 Million
|
Market
Size (2030)
|
USD
854.15 Million
|
CAGR
(2025-2030)
|
4.75%
|
Fastest
Growing Segment
|
Extrahepatic
Cholangiocarcinoma (EHC)
|
Largest
Market
|
North
America
|
Market Overview
Global Biliary Tract Cancers Market was valued at
USD 645.05 Million in 2024 and is anticipated to project Steady growth in the
forecast period with a CAGR of 4.75% through 2030. The Global Biliary Tract
Cancer Market is a dynamic and evolving sector within the broader field of
oncology. Biliary tract cancer, which includes cancers of the bile ducts and
gallbladder, poses unique challenges and opportunities for the healthcare
industry. This market overview aims to shed light on the current state of the Global
Biliary Tract Cancer Market.
Biliary tract cancer, while relatively rare
compared to some other cancers, has been on the rise in recent years. Factors
such as changing lifestyles, increased obesity rates, exposure to environmental
toxins, and specific risk factors like liver fluke infections have contributed
to the increasing incidence of this disease. Understanding the prevalence of
biliary tract cancer is crucial for market stakeholders to assess the potential
patient population.
Key Market Drivers
Increasing Incidence and Prevalence of Biliary Tract Cancers (BTCs)
The increasing incidence and prevalence of biliary tract cancers (BTCs) are key market drivers that significantly impact the Global Biliary Tract Cancers Market. According to the Global Burden of Disease Study, the global age-standardized incidence rate (ASR) for biliary tract cancers (BTCs) is 2.5 cases per 100,000 individuals. However, incidence rates vary significantly based on tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma, gallbladder cancer), geographic region, and gender, reflecting differences in genetic predisposition, environmental risk factors, and healthcare accessibility across populations. This rising trend is fueling demand for diagnostics, therapeutics, and supportive care solutions, creating lucrative opportunities for pharmaceutical companies, biotech firms, and healthcare providers. The growing number of diagnosed BTC cases worldwide is directly increasing the demand for treatment options. The Global Burden of Disease Study reported 139,500 deaths from biliary tract cancers (BTCs) in 2013, marking a 22% increase from the 115,400 deaths recorded in 1990. This rise corresponds to an increase in the age-standardized mortality rate, from 2.3 deaths per 100,000 individuals per year in 1990 to 3.4 per 100,000 per year in 2013, highlighting a growing disease burden and the need for enhanced diagnostic and treatment strategies. With biliary tract cancers being aggressive and often diagnosed at advanced stages, the need for effective chemotherapy, targeted therapies, and immunotherapies is rising. Increased drug sales for existing therapies. Greater investment in clinical research and drug development. Expansion of treatment facilities and specialized cancer centers.
BTCs are historically difficult to diagnose due to non-specific symptoms and late-stage detection. However, with the increasing prevalence of BTCs, there is a growing emphasis on early detection and screening programs, Advanced imaging techniques such as MRI, PET-CT, and contrast-enhanced ultrasound. Molecular diagnostics and biomarker testing, which help identify genetic mutations (e.g., FGFR2, IDH1) that guide personalized treatment. Liquid biopsies and next-generation sequencing (NGS), enabling non-invasive cancer detection and monitoring. The surge in early diagnosis is expanding the market for diagnostic tools and precision medicine, benefiting medical device manufacturers and biotech companies.As more BTC cases are being diagnosed, limitations of conventional chemotherapy (such as gemcitabine and cisplatin) are becoming evident. Increased investment in targeted therapies (e.g., FGFR inhibitors, IDH1 inhibitors). A shift towards immunotherapies, including checkpoint inhibitors like PD-1/PD-L1 inhibitors. The emergence of personalized medicine approaches, where treatment is tailored based on genetic profiling.This growing demand is driving pharmaceutical R&D and clinical trials, leading to a continuous pipeline of novel therapeutics. The increasing prevalence of BTCs is prompting healthcare providers and governments to expand oncology centers and improve cancer care services. The World Health Organization (WHO) has launched the Global Initiative on Childhood Cancer, aiming to achieve a minimum 60% global survival rate and alleviate suffering for all pediatric cancer patients by 2030. Since childhood cancers are generally not preventable, the initiative focuses on enhancing early diagnosis and expanding access to effective treatment, recognizing these as critical strategies for reducing the overall disease burden. Higher investment in specialized cancer hospitals and oncology-focused healthcare facilities. Increased availability of specialized oncologists and surgical teams skilled in BTC treatment. Greater government and private sector funding in oncology care infrastructure, especially in emerging markets such as Asia-Pacific and Latin America, where BTC prevalence is high. This expansion is creating growth opportunities for medical equipment manufacturers, healthcare service providers, and pharmaceutical companies.
Expanding Healthcare Infrastructure in Emerging Markets
The expansion of healthcare infrastructure in emerging markets is playing a pivotal role in driving the growth of the Global Biliary Tract Cancers (BTCs) Market. The World Bank Group has unveiled an ambitious initiative to help countries provide high-quality, affordable healthcare services to 1.5 billion people by 2030. This effort is part of a broader global strategy aimed at ensuring accessible, standardized care across all life stages, from infancy and childhood to adolescence and adulthood. As developing regions invest in modern healthcare facilities, specialized oncology centers, and advanced diagnostic capabilities, access to BTC diagnosis and treatment is improving. This trend is creating significant opportunities for pharmaceutical companies, medical device manufacturers, and healthcare service providers. Historically, many emerging markets have faced challenges in diagnosing and treating biliary tract cancers due to limited healthcare access, inadequate diagnostic facilities, and a lack of specialized oncology centers. The construction of new hospitals and cancer treatment centers equipped with modern oncology departments. Expanded availability of diagnostic imaging technologies, such as MRI, PET-CT scans, and endoscopic ultrasound, for early BTC detection. Enhanced training and recruitment of oncologists, radiologists, and surgical specialists, improving treatment quality and patient outcomes. As healthcare infrastructure strengthens, more patients can receive timely BTC diagnosis and access advanced treatment options, boosting market demand.
Governments in Asia-Pacific, Latin America, the Middle East, and Africa are making significant investments in oncology-focused healthcare infrastructure to address the rising burden of cancer. Public healthcare funding for the establishment of specialized cancer hospitals and research institutions. Tax incentives and subsidies for private sector investments in medical infrastructure. The introduction of universal healthcare schemes and reimbursement policies to cover cancer treatments, making BTC therapies more affordable and accessible. For example, countries like India, China, Brazil, and Saudi Arabia are witnessing increased investment in public-private partnerships (PPPs) in oncology, expanding the market potential for BTC drugs and medical technologies.

Download Free Sample Report
Key Market Challenges
Limited Awareness and Late-Stage Diagnoses
One of the foremost challenges facing the Global
Biliary Tract Cancer Market is the limited awareness among the general
population and healthcare providers regarding this particular cancer type.
Biliary tract cancer often presents with non-specific symptoms, leading to
delayed diagnoses. Many individuals and even some healthcare professionals may
not be adequately familiar with these symptoms, which can include jaundice,
abdominal pain, and unexplained weight loss.
The lack of early detection can result in patients
being diagnosed at advanced stages of the disease, when treatment options are
more limited and prognosis is less favorable. This not only hampers patient
outcomes but also reduces the potential market size for early-stage therapies
and interventions.
High Treatment Costs and Limited Access
The cost associated with the treatment of biliary
tract cancer can be prohibitively high, posing a significant challenge for both
patients and healthcare systems. Complex surgical procedures, chemotherapy,
targeted therapies, and supportive care measures all contribute to the
financial burden on patients and their families.
In many regions, limited access to affordable
healthcare services and advanced treatments exacerbates this challenge. This
can result in delayed or suboptimal treatment, which in turn affects market
growth by constraining the utilization of cutting-edge therapies and medical
technologies.
Regulatory Hurdles and Clinical Trial Limitations
Navigating the regulatory landscape for cancer
treatments is a complex and time-consuming process. Developing and gaining
approval for new therapies often involves rigorous clinical trials, extensive
documentation, and compliance with stringent regulatory standards. This can
extend the time it takes for innovative treatments to reach the market.
Recruiting patients for clinical trials can be
challenging, especially for rare cancers like biliary tract cancer. The limited
patient pool and stringent eligibility criteria can slow down the development
of new therapies and, consequently, hinder market growth. Also, regulatory
agencies may impose restrictions or delays in the approval of certain
treatments based on safety or efficacy concerns, further impeding the market's
progress.
The Global Biliary Tract Cancer Market faces
significant challenges related to limited awareness, late-stage diagnoses, high
treatment costs, limited access to care, and regulatory hurdles. These
obstacles can collectively slow down the market's growth potential, emphasizing
the need for concerted efforts in raising awareness, improving access to care,
and streamlining regulatory processes to address these challenges effectively.
Key Market Trends
Immunotherapy Revolutionizing Treatment Approaches
One of the most significant trends shaping the
Global Biliary Tract Cancer Market is the emergence of immunotherapy as a
promising treatment option. Immunotherapeutic agents, such as immune checkpoint
inhibitors, have shown remarkable efficacy in various cancer types, including
biliary tract cancer. These agents work by stimulating the body's immune system
to recognize and target cancer cells, offering new hope for patients.
The trend towards immunotherapy is driven by a
growing body of clinical evidence supporting its effectiveness. Clinical trials
have demonstrated prolonged survival rates and improved outcomes for patients
with advanced biliary tract cancer. This has led to increased research and
investment in immunotherapeutic approaches, with pharmaceutical companies
developing novel drugs and therapies targeting this specific cancer type.
Precision Medicine and Biomarker-Based Therapies
Precision medicine has gained prominence in the
treatment of biliary tract cancer, ushering in a new era of personalized
therapies. Advances in genomics and molecular profiling have enabled the
identification of specific biomarkers and genetic mutations associated with
this cancer type. These biomarkers serve as crucial indicators for treatment
selection, allowing oncologists to tailor therapies to individual patients.
Genetic mutations like FGFR2 alterations have been
identified in biliary tract cancer patients. Targeted therapies designed to
inhibit these mutations have shown promising results, demonstrating the
potential for more effective and less toxic treatments. The integration of
precision medicine not only enhances patient outcomes but also drives
pharmaceutical research and development efforts towards developing drugs that
target these specific biomarkers. This trend is expected to further accelerate
as our understanding of the genetic underpinnings of biliary tract cancer
continues to expand.
Multidisciplinary Collaborations and Comprehensive
Care
In recent years, a trend towards multidisciplinary
collaborations and comprehensive care models has emerged in the management of
biliary tract cancer. Healthcare providers are increasingly recognizing the
complexity of this cancer type, which often requires a combination of surgical,
medical, and radiation oncology approaches.
Multidisciplinary tumor boards, consisting of
specialists from various disciplines, are now commonly convened to discuss
individual patient cases and formulate personalized treatment plans. This
collaborative approach ensures that patients receive well-rounded care,
optimizing their chances of successful treatment outcomes. Comprehensive care
extends beyond medical treatments to encompass psychosocial support,
nutritional counseling, and pain management, among other aspects. This holistic
approach enhances the overall quality of life for patients and contributes to
their overall well-being during their cancer journey.
In summary, the Global Biliary Tract Cancer Market
is witnessing major trends that include the advent of immunotherapy, the rise
of precision medicine and biomarker-based therapies, and a shift towards
multidisciplinary collaborations and comprehensive care models. These trends
are reshaping the landscape of biliary tract cancer treatment, offering new
hope and improved outcomes for patients while driving innovation and investment
in the field.
Segmental Insights
Cancer Type Insights
Based on the category of Cancer Type, The Extrahepatic Cholangiocarcinoma (EHC) segment was emerging as the fastest-growing category within the Global Biliary Tract Cancers (BTCs) Market, driven by multiple market forces, including rising incidence rates, advancements in targeted therapies, and increasing awareness leading to earlier diagnoses. EHC, which affects the bile ducts outside the liver, is becoming increasingly prevalent worldwide, particularly in Asia-Pacific, Europe, and North America. Aging populations, as EHC is more common in older individuals. Higher prevalence of risk factors such as primary sclerosing cholangitis (PSC), liver fluke infections, and chronic biliary inflammation. Improved diagnostic capabilities, leading to higher detection rates. As EHC cases continue to rise, the demand for effective treatment options is driving significant market expansion. Unlike traditional chemotherapy, targeted therapies and immunotherapies are transforming the treatment landscape for EHC. FGFR (Fibroblast Growth Factor Receptor) inhibitors, such as pemigatinib and infigratinib, which are approved for EHC patients with FGFR2 gene fusions. IDH1 inhibitors, such as ivosidenib, targeting specific genetic mutations found in EHC cases. PD-1/PD-L1 checkpoint inhibitors, which are showing promise in immunotherapy-based approaches. With a growing pipeline of novel drugs and combination therapies, pharmaceutical companies are investing heavily in EHC-specific clinical trials, accelerating market expansion.

Download Free Sample Report
Regional Insights
North America emerged as the largest market in the global Biliary Tract Cancers market in 2024, holding the largest market share
in terms of value. North America, particularly the United States and Canada, has witnessed a rising incidence of biliary tract cancers, including cholangiocarcinoma (intrahepatic and extrahepatic) and gallbladder cancer. Aging population, as BTCs are more prevalent in individuals over 60 years old. High prevalence of risk factors, including obesity, metabolic disorders (such as diabetes), chronic liver diseases, and primary sclerosing cholangitis (PSC). Improved diagnostic capabilities, leading to higher detection rates compared to other regions. With a large and growing patient base, North America commands a significant share of the global BTC therapeutics and diagnostics market.
North America is home to major pharmaceutical and biotech firms actively engaged in BTC research, drug development, and commercialization. Emerging biotech firms developing novel approaches, such as immunotherapy and gene-targeted treatments. Strong pipeline of clinical trials, with North America accounting for a significant share of global BTC-focused trials. The presence of these industry giants, coupled with a robust regulatory framework, accelerates drug approvals and market growth. The high standard of oncology care in North America ensures early diagnosis and rapid access to cutting-edge therapies. Key factors driving this advantage include: Well-established cancer treatment centers, such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic, specializing in BTC research and treatment. Adoption of advanced diagnostic techniques, including liquid biopsies, genomic sequencing, and AI-driven imaging technologies, improving early detection.
Recent Developments
- In February 2025, A novel treatment approach for biliary tract cancer (BTC) is focusing on HER2-targeted therapies, aiming to improve patient outcomes by addressing specific molecular drivers of the disease. Experts suggest that expanding the range of targeted therapies could enhance treatment efficacy by matching patients with drugs tailored to the genetic profile of their tumors. In recent years, the U.S. Food and Drug Administration (FDA) has approved multiple precision therapies for BTC, targeting key molecular pathways. These include pemigatinib (Pemazyre) and futibatinib (Lytgobi), both FGFR2 inhibitors, and ivosidenib (Tibsovo), an IDH1 inhibitor. The continued advancement of HER2-directed treatments represents a significant step toward more personalized and effective BTC management.
- In January 2025, A newly launched clinical trial, sponsored by University College London (UCL) and University College London Hospitals (UCLH), aims to improve survival outcomes for patients with biliary tract cancer (BTC). The study focuses on personalized treatment strategies, using genetic profiling of individual tumors to match patients with targeted therapies most likely to be effective based on their unique molecular characteristics.
- In November 2024, The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab (Ziihera®) for the treatment of advanced and metastatic biliary tract cancers (BTC), including cholangiocarcinoma, in patients with high HER2 expression who have not responded to chemotherapy.
The approval is based on clinical trial results demonstrating zanidatamab’s efficacy in targeting HER2-positive BTC, offering a new therapeutic option for patients with limited treatment alternatives. The study leading to this breakthrough was co-led by Dr. James J. Harding, a gastrointestinal medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center (MSK). This marks a significant advancement in personalized treatment strategies for BTC patients.
- In September 2024, SystImmune, Inc., a clinical-stage biotechnology company, has announced that three abstracts on BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled for September 13–17 in Barcelona, Spain. BL-B01D1 is being co-developed under an exclusive license and collaboration agreement between SystImmune and Bristol Myers Squibb, with the goal of advancing targeted therapies for cancers driven by EGFR and HER3 pathways. These presentations at ESMO 2024 are expected to provide key insights into the therapeutic potential and clinical progress of this novel ADC.
- In April 2024, The U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to CTX-009, a bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract cancer (BTC) who have previously undergone therapy.
This designation is intended to expedite the development and regulatory review of CTX-009, recognizing its potential to address an unmet medical need in BTC. The therapy aims to improve clinical outcomes by simultaneously targeting DLL4 and VEGF-A pathways, which play critical roles in tumor progression and angiogenesis.
- In August 2023, Roche announces that the UK's
Medicines and Healthcare products Regulatory Agency (MHRA) has approved
Tecentriq SC (atezolizumab subcutaneous injection) for the treatment of
non-small cell lung cancer (NSCLC), bladder cancer, urothelial carcinoma,
breast cancer, and hepatocellular carcinoma (HCC).
Key Market Players
- Bristol-Myers
Squibb
- Eli Lilly
and Company
- F.
Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc
- Merck
& Co., Inc.
- Novartis
AG
- Pfizer
Inc.
- Sanofi SA
- Bayer AG
- AstraZeneca
plc
By Cancer Type
|
By End-User
|
By Region
|
- Intrahepatic Cholangiocarcinoma (ICC)
- Extrahepatic Cholangiocarcinoma
- Gallbladder Cancer
|
- Hospitals
- Specialty Cancer Centres
- Ambulatory Surgical Centres
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Biliary Tract Cancers
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Biliary Tract Cancers
Market, By
Cancer Type:
o Intrahepatic Cholangiocarcinoma (ICC)
o Extrahepatic Cholangiocarcinoma
o Gallbladder Cancer
- Biliary Tract Cancers
Market, By
End-User:
o Hospitals
o Specialty Cancer Centres
o Ambulatory Surgical Centres
o Others
- Biliary Tract Cancers
Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Biliary Tract Cancers Market.
Available Customizations:
Global Biliary Tract Cancers market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Biliary Tract Cancers Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at sales@techsciresearch.com